Short Interest in Silence Therapeutics Plc (NASDAQ:SLN) Increases By 24.2%
Short Interest in Silence Therapeutics Plc (NASDAQ:SLN) Increases By 24.2%
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 26,700 shares, a growth of 24.2% from the October 31st total of 21,500 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 42,400 shares, the short-interest ratio is presently 0.6 days.
沉默治疗公司(纳斯达克代码：SLN-GET评级)在11月份看到空头股数业务大幅增长。截至11月15日，空头股数共有26,700股，较10月31日的21,500股增长24.2%。目前，该公司0.1%的股份被卖空。以日均成交量42,400股计算，目前短息比率为0.6天。
Institutional Trading of Silence Therapeutics
沉默治疗的制度性交易
Several institutional investors have recently added to or reduced their stakes in SLN. TCG Crossover Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter worth $21,122,000. Lombard Odier Asset Management Europe Ltd acquired a new position in shares of Silence Therapeutics in the first quarter worth $29,669,000. BVF Inc. IL grew its stake in shares of Silence Therapeutics by 126.3% in the third quarter. BVF Inc. IL now owns 1,508,416 shares of the company's stock worth $14,888,000 after acquiring an additional 841,750 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Silence Therapeutics by 27.1% in the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock worth $18,350,000 after acquiring an additional 205,815 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Silence Therapeutics in the first quarter worth $16,742,000. Institutional investors and hedge funds own 72.14% of the company's stock.
几家机构投资者最近增持或减持了SLN的股份。TCG Crossover Management LLC在第三季度收购了Silence Treeutics价值21,122,000美元的新股票头寸。隆巴德·奥迪尔资产管理欧洲有限公司在第一季度收购了Silence Treeutics价值29,669,000美元的新股票头寸。第三季度，BVF Inc.在Silence Treateutics的持股增加了126.3%。BVF Inc.在上个季度增持了841,750股后，现在持有1,508,416股该公司股票，价值14,888,000美元。高盛股份有限公司在第一季度增持了寂静治疗公司的股份27.1%。高盛股份有限公司在上个季度增持了205,815股后，目前持有965,815股该公司股票，价值18,350,000美元。最后，Frazier生命科学管理公司在第一季度收购了Silence Treeutics价值16,742,000美元的新头寸。机构投资者和对冲基金持有该公司72.14%的股票。
Silence Therapeutics Price Performance
沉默治疗的价格表现
Shares of SLN stock traded up $0.56 during trading on Thursday, hitting $16.24. 44,029 shares of the stock traded hands, compared to its average volume of 36,002. Silence Therapeutics has a 52-week low of $7.80 and a 52-week high of $26.84. The firm's fifty day moving average price is $11.87 and its 200-day moving average price is $10.84. The firm has a market capitalization of $582.82 million, a P/E ratio of -10.51 and a beta of 0.82.
在周四的交易中，SLN股票的股价上涨了0.56美元，达到16.24美元。该股有44,029股易手，而其平均成交量为36,002股。Silent Treeutics的52周低点为7.80美元，52周高位为26.84美元。该公司的50日移动均线价格为11.87美元，200日移动均线价格为10.84美元。该公司的市值为5.8282亿美元，市盈率为-10.51，贝塔系数为0.82。
Analyst Ratings Changes
分析师评级发生变化
About Silence Therapeutics
关于沉默疗法
(Get Rating)
(获取评级)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Silent Treateutics公司是一家生物技术公司，专注于血液学、心血管和其他罕见和代谢适应症的新型核糖核酸(RNA)疗法的发现和开发。该公司的平台包括mRNAi GalNAc寡核苷酸发现平台，旨在准确靶向肝脏中特定的疾病相关基因。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is The Recovery Rally Here For SoFi?
- Is Apple Going To Rally Into Year End?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- 免费获取StockNews.com关于沉默治疗的研究报告(SLN)
- 卖空者对马伦汽车股票的看法仍然正确吗？
- La-Z-Boy倾斜到更舒适的水平
- 复苏集会是为SoFi而来的吗？
- 苹果会在年底前大涨吗？
- 放宽Covid规则会降低中国电动汽车制造商蔚来的风险吗？
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《沉默治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Silence Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。